Eiko Lifesciences Profit & Loss Annual

BSE: - | NSE: - | ISIN: - | Sector: -

53.99 -0.08 (-0.15%)Updated : 13 Jan 2026

Interim Data

Annual Data

Fiscal Period	2025	2024	2023	2022
Period End Date	Mar 25	Mar 24	Mar 23	Mar 22
Total Operating Expense	35.30	26.98	18.00	24.68
Other Net	0.71	0.18	0.85	0.58
Diluted Weighted Average Shares	1.30	1.03	0.96	0.90
Depreciation/ Amortization	0.74	0.66	0.63	0.56
Operating Income	2.36	0.95	0.32	0.73
Net Income	2.11	0.75	0.77	0.71
Income Availableto Com Excl Extra Ord	2.11	0.75	0.77	0.71
Other Operating Expenses Total	1.88	0.68	0.99	1.26
Net Income Before Taxes	3.06	0.98	1.03	0.94
Minority Interest	-0.21	-	-	-
Net Income After Taxes	2.32	0.75	0.77	0.71
Income Availableto Com Incl Extra Ord	2.11	0.75	0.77	0.71
Costof Revenue Total	32.66	25.41	16.09	22.58
Gross Profit	5.00	2.52	2.23	2.83
Interest Inc( Exp) Net- Non- Op Total	-0.01	-0.14	-0.15	-0.37
Unusual Expense( Income)	-0.34	-	-	-
Diluted Net Income	2.11	0.75	0.77	0.71
Provisionfor Income Taxes	0.75	0.23	0.26	0.24
period Type	-	-	-	-
Net Income Before Extra Items	2.11	0.75	0.77	0.71
Total Revenue	37.66	27.93	18.32	25.41
period Length	12.00	12.00	12.00	12.00
Revenue	37.66	27.93	18.32	25.41
Selling/ General/ Admin Expenses Total	0.37	0.22	0.29	0.28
Diluted Normalized EPS	1.42	0.73	0.80	0.78
Diluted EPS Excluding Extra Ord Items	1.62	0.73	0.80	0.78
Total Adjustmentsto Net Income	-	-	0.00	-
DPS- Common Stock Primary Issue	-	-	-	0.00